CSIMarket
 


Renovorx Inc   (RNXT)
Other Ticker:  
 

Renovorx Inc 's Working Capital Ratio

RNXT's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




RNXT Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 76.32 % - - - -
Y / Y Current Assets Change -49.08 % - - - -
Working Capital Ratio MRQ 8.39 10.01 9.92 17.36 29.06
Overall Ranking # # # # #
Seq. Current Liabilities Change -1.87 % -20.13 % 49.89 % 50.08 % -
Seq. Current Assets Change -17.73 % -19.36 % -14.36 % -10.37 % -



Working Capital Ratio third quarter 2022 Comment
Regardless of the sequential decrease in Current Liabilities, Working Capital Ratio detoriated to 8.39 above company average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry Renovorx Inc booked the highest Working Capital Ratio than Renovorx Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is RNXT most successful ?
Working Capital Ratio RNXT on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Renovorx Inc 's Current Liabilities $ 1 Millions Visit RNXT's Balance sheet
Renovorx Inc 's Current Assets $ 9 Millions Visit RNXT's Balance sheet
Source of RNXT's Sales Visit RNXT's Sales by Geography


Cumulative Renovorx Inc 's Working Capital Ratio

RNXT's Working Capital Ratio for the trailling 12 Months

RNXT Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 76.32 % - - - -
Y / Y Current Assets TTM Growth -49.08 % - - - -
Working Capital Ratio TTM 11.1 14.57 16.3 22.04 29.06
Total Ranking TTM # # 353 # 295 # #
Seq. Current Liabilities TTM Growth -1.87 % -20.13 % 49.89 % 50.08 % -
Seq. Current Assets TTM Growth -17.73 % -19.36 % -14.36 % -10.37 % -


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to decrease in Current Liabilities in the III. Quarter to $1.10 millions, average cumulative Working Capital Ratio decreased to 11.1 below the Renovorx Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry RNXT achieved the highest Working Capital Ratio. While Working Capital Ratio overall ranking has improved so far to 0, from total ranking in previous quarter at 329.

Explain Working Capital Ratio
Where is RNXT most successful ?
Working Capital Ratio RNXT on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market # 0


TTM Working Capital Ratio Statistics
High Average Low
16.55 15.56 14.57
(Mar 31 2022)   (Jun 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Dice Therapeutics Inc   22.96 $ 267.837  Millions$ 11.665  Millions
Pmv Pharmaceuticals Inc   22.75 $ 265.176  Millions$ 11.656  Millions
Eliem Therapeutics Inc   22.46 $ 133.171  Millions$ 5.928  Millions
Keros Therapeutics Inc   22.21 $ 245.875  Millions$ 11.070  Millions
Cassava Sciences Inc   22.06 $ 183.272  Millions$ 8.308  Millions
Janux Therapeutics Inc   21.08 $ 344.330  Millions$ 16.335  Millions
Ovid Therapeutics Inc   20.88 $ 140.537  Millions$ 6.732  Millions
Day One Biopharmaceuticals Inc   20.83 $ 380.513  Millions$ 18.271  Millions
Minerva Neurosciences Inc   20.41 $ 44.841  Millions$ 2.197  Millions
Lantern Pharma Inc   20.35 $ 62.020  Millions$ 3.047  Millions
Agios Pharmaceuticals Inc   19.54 $ 784.935  Millions$ 40.171  Millions
Forte Biosciences Inc   19.45 $ 44.594  Millions$ 2.293  Millions
Kura Oncology Inc   19.45 $ 436.391  Millions$ 22.441  Millions
Verve Therapeutics Inc   19.35 $ 561.630  Millions$ 29.018  Millions
Nuvalent Inc   18.90 $ 245.245  Millions$ 12.975  Millions
Catalyst Biosciences Inc   18.40 $ 30.246  Millions$ 1.644  Millions
Astria Therapeutics inc   18.40 $ 118.485  Millions$ 6.441  Millions
Stoke Therapeutics Inc   17.94 $ 264.601  Millions$ 14.749  Millions
Generation Bio Co   17.93 $ 310.558  Millions$ 17.318  Millions
Olema Pharmaceuticals inc   17.93 $ 225.058  Millions$ 12.552  Millions
Moonlake Immunotherapeutics  17.84 $ 88.539  Millions$ 4.962  Millions
Point Biopharma Global Inc   17.84 $ 296.231  Millions$ 16.608  Millions
Zomedica Corp   17.84 $ 127.103  Millions$ 7.126  Millions
Pardes Biosciences Inc   17.80 $ 214.041  Millions$ 12.028  Millions
Annovis Bio inc   17.60 $ 32.487  Millions$ 1.846  Millions
Akouos inc   17.30 $ 174.493  Millions$ 10.087  Millions
Immuneering Corp  17.28 $ 120.025  Millions$ 6.947  Millions
Syndax Pharmaceuticals Inc   17.19 $ 357.631  Millions$ 20.803  Millions
Kinnate Biopharma Inc   17.02 $ 261.175  Millions$ 15.343  Millions
Cerevel Therapeutics Holdings Inc   16.64 $ 998.658  Millions$ 60.020  Millions

Date modified: 2022-11-27T22:37:56+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

DKDC's Profile

Stock Price

DKDC's Financials

Business Description

Fundamentals

Charts & Quotes

DKDC's News

Suppliers

DKDC's Competitors

Customers & Markets

Economic Indicators

DKDC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071